Literature DB >> 30130526

Propranolol inhibits proliferation and invasion of hemangioma-derived endothelial cells by suppressing the DLL4/Notch1/Akt pathway.

Bin Sun1, Changxian Dong2, Hongzhao Lei1, Yubin Gong1, Miaomiao Li1, Yuanfang Zhang1, Hongyu Zhang1, Longlong Sun3.   

Abstract

Infantile hemangioma (IH) is one of the most common benign vascular tumors of infancy. Propranolol has been recently introduced for the treatment of IH. However, the mechanism of protective effect has not been fully understood. In this study, hemangioma-derived endothelial cells (HemECs) were isolated and treated with propranolol. The cell viability was measured by MTT assay, and the cell cycle arrest was detected using flow cytometry. Cell invasion was determined using transwell assay. The expressions of matrix metalloproteinase (MMP)-2, MMP-9, Delta-like 4 (DLL4), Notch1, Akt, p-Akt, and vascular endothelial growth factor (VEGF) were detected using western blot. HemECs were incubated with recombinant human DLL4 (rhDLL4) to investigate the role of DLL4/Notch1 in the effect of propranolol. The results showed that propranolol inhibited cell viability of HemECs in a time-dependent manner. Propranolol suppressed cell proliferation of HemECs by arresting cell progression at G0/G1 phase. Propranolol inhibited the invasion ability of HemECs and reduced the expression levels of MMP-2 and MMP-9 in HemECs. Besides, propranolol treatment blocked the DLL4/Notch1 and Akt signaling and inhibited VEGF expression in HemECs. Treatment with rhDLL4 activated the Akt signaling and attenuated the effect of propranolol on HemECs. Our data indicated that propranolol inhibited the cell proliferation and invasion of HemECs. The effect was possibly involved in the DLL4/Notch1/Akt signaling pathway.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  DLL4/Notch1/Akt signaling; Hemangioma-derived endothelial cells (HemECs); Infantile hemangioma (IH); Invasion; Proliferation; Propranolol

Mesh:

Substances:

Year:  2018        PMID: 30130526     DOI: 10.1016/j.cbi.2018.08.018

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  7 in total

Review 1.  Efficacy and adverse effects of oral propranolol in infantile hemangioma: a meta-analysis of comparative studies.

Authors:  Hao Yang; Dong-Lai Hu; Qiang Shu; Xiao-Dong Guo
Journal:  World J Pediatr       Date:  2019-07-24       Impact factor: 2.764

2.  DNAJC12 activated by HNF1A enhances aerobic glycolysis and drug resistance in non-small cell lung cancer.

Authors:  Jin Wang; Haihua Huang; Fabing Liu
Journal:  Ann Transl Med       Date:  2022-04

3.  The β-adrenergic receptor antagonist propranolol offsets resistance mechanisms to chemotherapeutics in diverse sarcoma subtypes: a pilot study.

Authors:  Letizia Porcelli; Marianna Garofoli; Roberta Di Fonte; Livia Fucci; Mariateresa Volpicella; Sabino Strippoli; Michele Guida; Amalia Azzariti
Journal:  Sci Rep       Date:  2020-06-26       Impact factor: 4.379

4.  Non-beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma.

Authors:  Caroline T Seebauer; Matthew S Graus; Lan Huang; Alex McCann; Jill Wylie-Sears; Frank Fontaine; Tara Karnezis; David Zurakowski; Steven J Staffa; Frédéric Meunier; John B Mulliken; Joyce Bischoff; Mathias Francois
Journal:  J Clin Invest       Date:  2022-02-01       Impact factor: 14.808

5.  Propranolol vs. steroids in the treatment of infantile hemangiomas: A meta-analysis.

Authors:  Yiting You; Yadong Li; Yiting Xiao; Jinsong Zhang
Journal:  Mol Clin Oncol       Date:  2021-06-10

6.  MiR-19-3p Induces Tumor Cell Apoptosis via Targeting FAS in Rectal Cancer Cells.

Authors:  Ying-Feng Su; Yi-Feng Zang; Yu-Hong Wang; Yin-Lu Ding
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

Review 7.  A Primer on a Comprehensive Genetic Approach to Vascular Anomalies.

Authors:  Alexandra J Borst; Taizo A Nakano; Francine Blei; Denise M Adams; Jessica Duis
Journal:  Front Pediatr       Date:  2020-10-19       Impact factor: 3.418

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.